fertility awareness method, natural family planning, FAM, NFP, what is a fertility awareness method, what are FAMs, what is NFP, chart, charting, chart FAMs, birth control side effects, birth control alternatives, natural birth control, birth control without hormones, hormone-free birth control, women's health, sexual health, family planning, contraception, birth control, the Pill, infertility, cures for infertility, infertility treatment, natural infertility treatments, improving fertility, understanding fertility

Birth Control Side Effects

Click a topic to learn more about the following birth control side effects:

Birth control side effects

Many women dislike the idea of ingesting artificial hormones or of having devices implanted in their bodies. Increasingly, the effects of hormonal birth control and other forms of contraception on women’s health and wellbeing are becoming more evident.

Some of the side effects resulting from the use of hormonal contraceptives include:

  • loss of libido
  • rashes
  • discoloration of the skin (melasma/chloasma)
  • changes in weight or appetite
  • nausea, vomiting
  • migraines
  • mood changes, including depression
  • aggravation of varicose veins
  • gastrointestinal symptoms (pain, cramps, bloating)
  • spotting
  • vaginitis (yeast infection)
  • vitamin deficiencies
  • water retention
  • vision impairment
  • liver malfunction (jaundice)

Further, numerous studies show increased risk of cancer and increased risk of blood clots resulting from the use of hormonal contraceptives.

Thousands of lawsuits have been filed in recent years against manufacturers of various birth control pills for serious health complications suffered, including:

  • Heart attack
  • Stroke
  • Deep vein thrombosis (blood clots in legs)
  • Pulmonary embolism (blockages in the lungs)
  • Gallbladder disease

Likewise, thousands of women have filed claims against the manufacturers of the Mirena® IUD (intrauterine devices) for serious side effects. In general, IUDs increase risk of:

  • Ectopic pregnancy (tubal pregnancy)
  • Pelvic inflammatory disease
  • Abnormal bleeding
  • Infection
  • Displacement of the device, which can lead to serious complications.

Hundreds of women have also reported adverse reactions to the Essure® sterilization procedure, with at least 91 women having to undergo a hysterectomy as a result of damages. Users of the copper IUD Paragard® have reported symptoms of copper toxicity.

To learn more about birth control side effects, see the articles below.

Women seeking to avoid birth control side effects can learn more about fertility awareness methods as natural alternatives to pharmaceutical birth control.

Mirena, Essure are registered trademarks of Bayer. Paragard is a registered trademark of CooperSurgical, Inc.

References

Click a subtopic below to view scientific references for each of the following items and their connections to birth control use. 

CROHN’S DISEASE

Boyko EJ, Theis MK, Vaughan TL, and Nicol-Blades B. Increased risk of inflammatory bowel disease associated with oral contraceptive use. American Journal of Epidemiology 1994; 140:268–278.

Calkins BM, Mendeloff AI, and Garland C. Inflammatory bowel disease in oral contraceptive users. Gastroenterology 1986; 91: 523–524.

Cornish JA, Tan E, Simillis C, Clark SK, Teare J, and Tekkis PP. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysisAmerican Journal of Gastroenterology 2008; 103:2394–2400.

Corrao G, Tragnone A, Caprilli R, Trallori G, Papi C, Andreoli A, Di Paolo M, Riegler G, Rigo GP, Ferraù O, Mansi C, Ingrosso M, and Valpiani D. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC). International Journal of Epidemiology 1998; 27:397–404.

García Rodríguez LA, González-Pérez A, Johansson S, and Wallander MA. Risk factors for inflammatory bowel disease in the general populationAlimentary Pharmacology & Therapeutics 2005; 22:309–315.

Godet PG, May GR, and Sutherland LR. Meta-analysis of the role of oral contraceptive agents in inflammatory bowel diseaseGut 1995; 37:668–673.

Halfvarson J, Jess T, Magnuson A, Montgomery SM, Orholm M, Tysk C, Binder V, and Järnerot G. Environmental factors in inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin population. Inflammatory Bowel Disease 2006; 12:925–933.

Han DY, Fraser AG, Dryland P, and Ferguson LR. Environmental factors in the development of chronic inflammation: a case-control study on risk factors for Crohn’s disease within New ZealandMutation Research 2010; 690:116–122.

Katschinski B. [Smoking and ovulation inhibitor in inflammatory bowel diseases]. Medizinische Klinik (Munich, Germany) 88 Suppl 1993; 1:5–8.

Khalili H, Higuchi LM, Ananthakrishnan AN, Richter JM, Feskanich D, Fuchs CS, and Chan AT. Oral contraceptives, reproductive factors and risk of inflammatory bowel diseaseGut 2013; 62:1153–1159.

Lashner BA, Kane SV, and Hanauer SB. Lack of association between oral contraceptive use and Crohn’s disease: a community-based matched case-control studyGastroenterology 1989; 97:1442–1447.

Lesko SM, Kaufman DW, Rosenberg L, Helmrich SP, Miller DR, Stolley PD, and Shapiro S. Evidence for an increased risk of Crohn’s disease in oral contraceptive users. Gastroenterology 1985; 89:1046–1049.

Logan RF and Kay CR. Oral contraception, smoking and inflammatory bowel disease—findings in the Royal College of General Practitioners Oral Contraception StudyInternational Journal of Epidemiology 1989; 18: 105–107.

Lowe AM, Roy PO, Poulin M, Michel P, Bitton A, St-Onge L, and Brassard P. Epidemiology of Crohn’s disease in Quebec, CanadaInflammatory Bowel Disease 2009; 15:429–435.

Ng SC, Woodrow S, Patel N, Subhani J, and Harbord M. Role of genetic and environmental factors in British twins with inflammatory bowel diseaseInflammatory Bowel Disease 2012; 18:725–736.

Persson PG, Leijonmarck CE, Bernell O, Hellers G, and Ahlbom A. Risk indicators for inflammatory bowel diseaseInternational Journal of Epidemiology 1993; 2(2):268–272.

Sandler RS, Wurzelmann JI, and Lyles CM. Oral contraceptive use and the risk of inflammatory bowel diseaseEpidemiology 1992; 3:374–378.

Vcev A, Pezerovic D, Jovanovic Z, Nakic D, Vcev I, and Majnarić L. A retrospective, case-control study on traditional environmental risk factors in inflammatory bowel disease in Vukovar-Srijem County, north-eastern Croatia 2010Wiener Klinische Wochenschrift 2015; 127:345–354.

Vessey M, Jewell D, Smith A, Yeates D, and McPherson K. Chronic inflammatory bowel disease, cigarette smoking, and use of oral contraceptives: findings in a large cohort study of women of childbearing ageBritish Medical Journal (Clinical Research Edition) 1986; 292:1101–1113.

ULCERATIVE COLITIS

Boyko EJ, Theis MK, Vaughan TL, and Nicol-Blades B. Increased risk of inflammatory bowel disease associated with oral contraceptive useAmerican Journal of Epidemiology 1994; 140:268–278.

Calkins BM, Mendeloff AI, and Garland C. Inflammatory bowel disease in oral contraceptive usersGastroenterology 1986; 91:523–524.

Cornish JA, Tan E, Simillis C, Clark SK, Teare J, and Tekkis PP. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysisAmerican Journal of Gastroenterology 2008; 103:2394–2400.

Corrao G, Tragnone A, Caprilli R, Trallori G, Papi C, Andreoli A, Di Paolo M, Riegler G, Rigo GP, Ferraù O, Mansi C, Ingrosso M, and Valpiani D. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC)International Journal of Epidemiology 1998; 27:397–404.

García Rodríguez LA, González-Pérez A, Johansson S, and Wallander MA. Risk factors for inflammatory bowel disease in the general populationAlimentary Pharmacology & Therapeutics 2005; 22:309–315.

Godet PG, May GR, and Sutherland LR. Meta-analysis of the role of oral contraceptive agents in inflammatory bowel diseaseGut 1995; 37:668–673.

Halfvarson J, Jess T, Magnuson A, Montgomery SM, Orholm M, Tysk C, Binder V, and Järnerot G. Environmental factors in inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin populationInflammatory Bowel Disease 2006; 12:925–933.

Khalili H, Higuchi LM, Ananthakrishnan AN, Richter JM, Feskanich D, Fuchs CS, and Chan AT. Oral contraceptives, reproductive factors and risk of inflammatory bowel diseaseGut 2013; 62:1153–1159.

Lashner BA, Kane SV, and Hanauer SB. Lack of association between oral contraceptive use and ulcerative colitisGastroenterology 1990; 99:1032–36.

Logan RF and Kay CR. Oral contraception, smoking and inflammatory bowel disease—findings in the Royal College of General Practitioners Oral Contraception StudyInternational Journal of Epidemiology 1989;18:105–107.

Ng SC, Woodrow S, Patel N, Subhani J, and Harbord M. Role of genetic and environmental factors in British twins with inflammatory bowel diseaseInflammatory Bowel Disease 2012; 18:725–736.

Parrello T, Pavia M, Angelillo IF, Monteleone G, Riegler G, Papi G, D’Incà R, Annese V, Tonelli F, Caprilli R, and Pallone F. Appendectomy is an independent protective factor for ulcerative colitis: results of a multicentre case control study. The Italian Group for the Study of the Colon and Rectum (GISC)Italian Journal of Gastroenterology and Hepatology 1997; 29:208–211.

Persson PG, Leijonmarck CE, Bernell O, Hellers G, and Ahlbom A. Risk indicators for inflammatory bowel diseaseInternational Journal of Epidemiology 1993; 22:268–272.

Sandler RS, Wurzelmann JI, and Lyles CM. Oral contraceptive use and the risk of inflammatory bowel diseaseEpidemiology 1992; 3:374–378.

Vcev A, Pezerovic D, Jovanovic Z, Nakic D, Vcev I, and Majnarić L. A retrospective, case-control study on traditional environmental risk factors in inflammatory bowel disease in Vukovar-Srijem County, north-eastern Croatia, 2010Wiener Klinische Wochenschrift 2015; 127:345–354.

Vessey M, Jewell D, Smith A, Yeates D, and McPherson K. Chronic inflammatory bowel disease, cigarette smoking, and use of oral contraceptives: findings in a large cohort study of women of childbearing age. British Medical Journal (Clinical Research Edition) 1986; 292:1101–1113.

SYSTEMIC LUPUS ERYTHEMATOSUS

Bernier MO, Mikaeloff Y, Hudson M, and Suissa S. Combined oral contraceptive use and the risk of systemic lupus erythematosusArthritis and Rheumatism 2009; 61:476–481.

Cooper GS, Dooley MA, Treadwell EL, St Clair EW, and Gilkeson GS. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study. Arthritis and Rheumatism 2002; 46:1830–1839.

Costenbader KH, Feskanich D, Stampfer MJ, and Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in womenArthritis and Rheumatism 2007; 56:1251–1262.

Grimes DA, LeBolt SA, Grimes KR, and Wingo PA. Systemic lupus erythematosus and reproductive function: A case control studyAmerican Journal of Obstetrics and Gynecology 1985; 153:179–186.

Sanchez-Guerrero J, Karlson EW, Liang MH, Hunter DJ, Speizer FE, and Colditz GA. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis and Rheumatism 1997; 40: 804–808.

Strom BL, Reidenberg MM, West S, Snyder ES, Freundlich B, and Stolley PD. Shingles, allergies, family medical history, oral contraceptives, and other potential risk factors for systemic lupus erythematosusAmerican Journal of Epidemiology 1994; 140:632–642.

Zonana-Nacach A, Rodríguez-Guzmán LM, Jiménez-Balderas FJ, Camargo-Coronel A, Escobedo-de la Peña J, and Fraga A. [Risk factors associated with systemic lupus erythematosis in a Mexican population]. Salud Pública de México 2002; 44:213–218.

MULTIPLE SCLEROSIS

Alonso A, Jick SS, Olek MJ, Ascherio A, Jick H, and Hernán MA. Recent use of oral contraceptives and the risk of multiple sclerosisArchives of Neurology 2005; 62:1362–1365.

Hellwig K, Chen LH, Stancyzk FZ, and Langer-Gould AM. Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome SusceptibilityPLoS One 2016; 11:e0149094. Doi:10.1371/journal.pone.0149094.

Hernán MA, Hohol MJ, Olek MJ, Spiegelman D, and Ascherio A. Oral contraceptives and the incidence of multiple sclerosisNeurology 2000; 55:848–854.

Kotzamani D, Panou T, Mastorodemos V, Tzagournissakis M, Nikolakaki H, Spanaki C, and Plaitakis A. Rising incidence of multiple sclerosis in females associated with urbanization. Neurology 2012; 78:1728–1735.

Thorogood M, and Hannaford PC. The influence of oral contraceptives on the risk of multiple sclerosisBritish Journal of Obstetrics and Gynaecology 1998; 105:1296–1299.

Villard-Mackintosh L, and Vessey MP. Oral contraceptives and reproductive factors in multiple sclerosis incidenceContraception 1993; 47:161–168.

INTERSTITIAL CYSTITIS

Champaneria R, D’Andrea RM, and Latthe PM. Hormonal contraception and pelvic floor dysfunction: a systematic review. Int Urogynecol J 2016; 27:709–722.

El Khoudary SR, Talbott EO, Bromberger JT, Chang CC, Songer TJ, and Davis EL. Severity of interstitial cystitis symptoms and quality of life in female patientsJournal of Womens Health (Larchmont) 2009; 18:1361–1368. Doi: 10.1089/jwh.2008.1270.

Gardella B, Porru D, Nappi RE, Daccò MD, Chiesa A, and Spinillo A. Interstitial cystitis is associated with vulvodynia and sexual dysfunction—a case-control studyThe Journal of Sexual Medicine 2011; 8:1726–1734. Doi: 10.1111/j.1743-6109.2011.02251.x. Epub 2011 Apr 7.

Konkle K, Berry SH, Elliott MN, Hilton L, Suttorp MJ, Clauw DJ, and Clemens JQ. Comparison of an interstitial cystitis/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology studyJournal of Urology 2012; 187:508–512.

VENOUS THROMBOEMBOLISM

Bloemenkamp KWM, Rosendaal FR, Büller HR, Helmerhorst FM, Colly LP, and Vandenbroucke JP. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral biasArch Intern Med 1999; 159:65–70.

Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, and Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third- generation progestagenLancet 1995; 346:1593–1596.

Dinger J, Assmann A, M€ohner S, and Minh TD. Risk of venous thromboembolism and the use of dienogestand drospirenone-containing oral contraceptives: results from a German case-control studyJ Fam Plann Reprod Health Care 2010; 36:123–129.

Dinger J, Bardenheuer K, and Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenonecontaining combined oral contraceptives: final results from the International Active surveillance Study of Women Taking Oral ContraceptivesContraception 2014; 89(4):253–263.

Dinger JC, Heinemann LAJ, and Ku¨hl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on oral contraceptives based on 142,475 women years of observationContraception 2007; 75:344–354.

Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, and Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptivesLancet 1997; 349:83–88.

Food and Drug Administration, Office of surveillance and epidemiology. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. FDA. 2011; http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf.

Gomer K. Women, Birth Control Pills, and Thrombophilia: An Analysis of Risk Communication Kerry Gomer, Clemson University. 2009; https://tigerprints.clemson.edu/cgi/viewcontent.cgi?referer=&httpsredir=1&article=1573&context=all_theses.

Gronich N, Lavi I, and Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort studyCMAJ 2011; 183(18):E1319-25.

Jick H, Jick SS, Gurewich V, Myers MW, and Vasilakis C. Risk of ideopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsLancet 1995; 346:1589-1593.

Jick SS, and Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims dataBritish Medical Journal 2011; 340:d2151.

Keenan L, Kerr T, Duane M, and Van Gundy K. Systematic Review of Hormonal Contraception and Risk of Venous ThrombosisThe Linacre Quarterly 2018; 85(4):470–477.

Le Moigne E, Delluc A, Tromeur C, Nowak E, Mottier D, Lacut K, and Le Gal G. Risk of recurrent venous thromboembolism among young women after a first event while exposed to combined oral contraception versus not exposed to: a cohort studyThromb Res 2013; 132:51–55.

Lewis MA, MacRae KD, Kűhl-Habich D, Bruppacher R, Heinemann LA, and Spitzer WO. The differential risk of oral contraceptives: the impact of full exposure historyHum Re prod 1999; 14:1493–1499.

Lidegaard Ø, Edstr€om B, and Kreiner S. Oral contraceptives and venous thromboembolism. A five-year national case-control studyContraception 2002; 65:187–196.

Lidegaard Ø, Løkkegaard E, Svendsen AL, and Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up studyBritish Medical Journal 2009; 339:b2890.

Lidegaard Ø, Nielsen LH, Skovlund CW, and Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10British Medical Journal 2012; 344:e2990.

Lidegaard Ø,Nielsen LH, Skovlund CW, Skjeldestad FE, and Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and estrogen doses: Danish cohort study 2001–2009British Medical Journal 2011; 343:d6423.

[19] Lidegaard Ø. Hormonal contraception, thrombosis and age. Expert Opin Drug Saf 2014; 13:1353–360.

Parkin L, Sharples K, Hernandez RK, and Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research DatabaseBritish Medical Journal 2011; 340:d2139.

Parkin L, Skegg DCG, Wilson M, Herbison GP, and Paul C. Oral contraceptives and fatal pulmonary embolismLancet 2000; 355:2133–2134.

Peck R and Norris CW. Significant Risks of Oral Contraceptives (OCPs) Linacre Q 2012; 79(1): 41–56. Published online 2012 Feb 1. Doi: 10.1179/002436312803571447.

Phillippe HM, Hornsby LB, Treadway S, Armstrong EM, and Bellone JM. Inherited thrombophiliaJ Pharm Pract 2014; 27:227–233.

Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, and MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control studyBritish Medical Journal 1996; 312:83-88.

Todd J-C, Lawrenson R, Farmer RDT, Williams TJ, and Leydon GM. Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus databaseHum Reprod 1999; 14:1500–1505.

Van Hylckama VA, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, and Rosendaal FR. The Venous Thrombotic Risk of Oral Contraceptives, Effects of Estrogen Dose and Progestogen Type: Results of the MEGA Case-Control StudyBritish Medical Journal 2009; 339:b2921. Doi:10.1136/bmj.b2921.

Vinogradova Y, Coupland C and Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databasesBritish Medical Journal 2015; 350:h2135. Doi: https://doi.org/10.1136/bmj.h2135 (Published 26 May 2015).

World Health Organisation Collaborative Study on Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low estrogen oral contraceptives on venous thromboembolic diseaseLancet 1995; 346:1582–1588.

World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control studyLancet 1995; 346:1575-1582.

Yasmin Prescribing Information: Highlights of Yasmin Prescription Information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf.

ATHEROSCLEROSIS AND CARDIOVASCULAR EVENTS

Bagdade JD and Subbaiah PV. Serum from Oral Contraceptive Users Stimulates Growth of Arterial Smooth Muscle CellsAHA Journals, Arteriosclerosis 1982; 2(2):170–176.

Beral V. Cardiovascular disease mortality trends and oral contraceptive use in young womenLancet 1976; 2:1047–1052.

Fallah S, Nouroozi V, Seifi M, Samadikuchaksaraei A, and Aghdashi EM. Influence of oral contraceptive pills on homocysteine and nitric oxide levels: as risk factors for cardiovascular diseaseJ Clin Lab Anal 2012; 26:120–123.

Hennekens CH, and MacMahon B. Oral contraceptive and myocardial infarctionEngl J Med 1977; 296:1166–1167.

Hickson SS, Miles KL, McDonnell BJ, Yasmin, Cockcroft JR, Wilkinson IB, McEniery CM; ENIGMA Study Investigators. Use of the oral contraceptive pill is associated with increased large artery stiffness in young women: the ENIGMA studyHypertens 2011; 29(6):1155–1159.

Heidarzadeh Z, Asadi B, Saadatnia M, Ghorbani A, and Fatehi F. The Effect of Low-dose Combined Oral Contraceptive Pills on Brachial Artery Endothelial Function and Common Carotid Artery Intima–Media ThicknessJournal of Stroke and Cerebrovascular Diseases 2014; 23:675–680.

Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, and Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraceptionEngl J Med 2012; 366:2257–2266.

Priest SE, Shenouda N, and MacDonald MJ. Effect of sex, menstrual cycle phase, and monophasic oral contraceptive pill use on local and central arterial stiffness in young adultsAm J Physiol Heart Circ Physiol 2018; 315(2):H357-H365.

BREAST CANCER

Adams-Campbell LL, Makambi KH, Frederick WA, Gaskins M, Dewitty RL, and McCaskill-Stevens W. Breast cancer risk assessments comparing Gail and CARE models in African-American womenBreast J. 15 Suppl 2009; 1:S72–75.

Amadou A, Fabre A, Torres-Mejía G, Ortega-Olvera C, Angeles-Llerenas A, McKenzie F, Biessy C, Hainaut P, and Romieu I. Hormonal therapy and risk of breast cancer in Mexican womenPLoS One 2013; 8:e79695.

Beaber EF, Buist DS, Barlow WE, Malone KE, Reed SD, and Li CI. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of ageCancer Res 2014a; 74:4078–4089.

Beaber EF, Malone KE, Tang MT, Barlow WE, Porter PL, Daling JR, and Li CI. Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomarkers Prev 2014b; 23:755–764.

Beji NK and Reis N. Risk factors for breast cancer in Turkish women: a hospital-based case-control studyEur J Cancer Care (Engl). 2007; 16:178–184.

Bethea TN, Rosenberg L, Hong CC, Troester MA, Lunetta KL, Bandera EV, Schedin P, Kolonel LN, Olshan AF, Ambrosone CB, and Palmer JR. A case-control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast Cancer Epidemiology and Risk ConsortiumBreast Cancer Res 2015; 17:22. Doi:10.1186/s13058-015-0535-x.

Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J, Peock S, Eeles RA, Cook M, Chu C, Noguès C, Lasset C, Berthet P, Meijers-Heijboer H, Gerdes AM, Olsson H, Caldes T, van Leeuwen FE, and Rookus MA. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating GroupJ Clin Oncol 2007; 25:3831–3836.

Delort L, Kwiatkowski F, Chalabi N, Satih S, Bignon YJ, and Bernard-Gallon DJ. Risk factors for early age at breast cancer onset—the “COSA program” population-based studyAnticancer Res 2007; 27:1087–1094.

Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, and Malone KE. Risk factors for triple-negative breast cancer in women under the age of 45 yearsCancer Epidemiol Biomarkers Prev 2009; 18:1157–1166.

Figueiredo JC, Haile RW, Bernstein L, Malone KE, Langholz B, Lynch CF, Bertelsen L, Capanu M, Concannon P, Borg A, Børresen-Dale AL, Diep A, Teraoka S, Torngren T, Xue S, and Bernstein JL. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE StudyBreast Cancer Res Treat 2010; 120:175–183.

Folger SG, Marchbanks PA, McDonald JA, Bernstein L, Ursin G, Berlin JA, Daling JR, Norman SA, Strom BL, Weiss LK, Simon MS, Burkman RT, Malone KE, and Spirtas R. Risk of breast cancer associated with short-term use of oral contraceptivesCancer Causes Control 2007; 18:189–198.

Friebel TM, Domchek SM, and Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysisJ Natl Cancer Inst 2014; 106(6):dju091. Doi: 10.1093/jnci/dju091.

Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC; kConFab Investigators; Ontario Cancer Genetics Network Investigators, and Whittemore AS. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50Cancer Epidemiol Biomarkers Prev 2006; 15:1863–1870.

Heikkinen S, Koskenvuo M, Malila N, Sarkeala T, Pukkala E, and Pitkäniemi J. Use of exogenous hormones and the risk of breast cancer: results from self-reported survey data with validity assessmentCancer Causes Control 2016; 27:249–258.

Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W, Stampfer MJ, and Willett WC. Oral contraceptive use and breast cancer: a prospective study of young womenCancer Epidemiol Biomarkers Prev 2010; 19:2496–2502.

Ichida M, Kataoka A, Tsushima R, and Taguchi T. No increase in breast cancer risk in Japanese women taking oral contraceptives: a case-control study investigating reproductive, menstrual and familial risk factors for breast cancerAsian Pac J Cancer Prev 2015; 16:3685–3690.

Jernström H, Loman N, Johannsson OT, Borg A, and Olsson H. Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testingEur J Cancer 2005; 41:2312–2320.

Kahlenborn C, Modugno F, Potter DM, and Severs WB. Oral Contraceptive Use as a Risk Factor for Premenopausal Breast Cancer: A Meta-analysisMayo Clin Proc 2006; 81:1290–1302.

Kotsopoulos J, Lubinski J, Moller P, Lynch HT, Singer CF, Eng C, Neuhausen SL, Karlan B, Kim-Sing C, Huzarski T, Gronwald J, McCuaig J, Senter L, Tung N, Ghadirian P, Eisen A, Gilchrist D, Blum JL, Zakalik D, Pal T, Sun P, and Narod SA; Hereditary Breast Cancer Clinical Study Group. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriersBreast Cancer Res Treat 2014; 143:579–586.

Lee E, Ma H, McKean-Cowdin R, Van Den Berg D, Bernstein L, Henderson BE, and Ursin G. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based studyCancer Epidemiol Biomarkers Prev 2008; 17:3170–3178.

Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, and Malone KE. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res 2012; 72:2028–2035.

Lumachi F, Frigo AC, Basso U, Tombolan V, and Ermani M. Estrogen therapy and risk of breast cancer in postmenopausal women: a case-control study and results of a multivariate analysisMenopause 2010; 17:524–528.

Lund E, Bakken K, Dumeaux V, Andersen V, and Kumle M. Hormone replacement therapy and breast cancer in former users of oral contraceptives–The Norwegian Women and Cancer study. Int J Cancer 2007; 121:645–648.

Ma H, Bernstein L, Ross RK, and Ursin G. Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparisonBreast Cancer Res 2006; 8:R39.

Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, Ursin G, Burkman RT, Simon MS, Malone KE, Strom BL, McDonald JA, Press MF, and Bernstein L. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women’s contraceptive and reproductive experiences studyCancer Res 2010; 70:575–587.

Mehrgou A and Akouchekian M. The importance of BRCA1 and BRCA2 genes mutations in breast cancer developmentMed J Islam Repub Iran 2016; 30:369.

Milne RL, Knight JA, John EM, Dite GS, Balbuena R, Ziogas A, Andrulis IL, West DW, Li FP, Southey MC, Giles GG, McCredie MR, Hopper JL, and Whittemore AS. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutationsCancer Epidemiol Biomarkers Prev 2005; 14:350–356.

Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, and Myers ER. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysisJ Clin Oncol 2013;31(33): 4188–4198. Doi:10.1200/JCO.2013.48.9021.

Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, and Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancerEngl J Med 2017; 377:2228–2239.

Ozmen V, Ozcinar B, Karanlik H, Cabioglu N, Tukenmez M, Disci R, Ozmen T, Igci A, Muslumanoglu M, Kecer M,and Soran A. Breast cancer risk factors in Turkish women—a University Hospital based nested case control studyWorld J Surg Oncol 2009; 7:37.

Parkin DM. Cancers attributable to exposure to hormones in the UK in 2010British Journal of Cancer 2011; 105: S42–S48.

Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC, Rohan TE, and Li CI. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancerJ Natl Cancer Inst 2011; 103:470–477.

Poosari A, Promthet S, Kamsa-ard S, Suwanrungruang K, Longkul J, and Wiangnon S. Hormonal contraceptive use and breast cancer in Thai women. J Epidemiol 2014; 24:216–220.

Rosenberg L, Zhang Y, Coogan PF, Strom BL, and Palmer JR. A case-control study of oral contraceptive use and incident breast cancerAm J Epidemiol 2008; 169:473–479.

Rosenberg L, Boggs DA, Wise LA, Adams-Campbell LL, and Palmer JR. Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American womenCancer Epidemiol Biomarkers Prev 2010; 19:2073–2079.

Samson ME, Adams SA, Mulatya CM, Zhang J, Bennett CL, Hebert J, and Steck SE. Types of oral contraceptives and breast cancer survival among women enrolled in Medicaid: A competing-risk modelMaturitas 2017; 95:42–49.

Silvera SA, Miller AB, and Rohan TE. Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort studyCancer Causes Control. 2005; 16:1059–1063.

Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, and Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in FinlandObstet Gynecol 2014; 124 (2 Pt 1): 292–299.

Sweeney C, Giuliano AR, Baumgartner KB, Byers T, Herrick JS, Edwards SL, and Slattery ML. Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white womenInt J Cancer 2007; 121:2517–2523.

Thorbjarnardottir T, Olafsdottir EJ, Valdimarsdottir UA, Olafsson O, and Tryggvadottir L. Oral contraceptives, hormone replacement therapy and breast cancer risk: a cohort study of 16 928 women 48 years and olderActa Oncol 2014; 53:752–758.

Trivers KF, Gammon MD, Abrahamson PE, Lund MJ, Flagg EW, Moorman PG, Kaufman JS, Cai J, Porter PL, Brinton LA, Eley JW, and Coates RJ. Oral contraceptives and survival in breast cancer patients aged 20 to 54 yearsCancer Epidemiol Biomarkers Prev 2007; 16:1822–1827.

Veisy A, Lotfinejad S, Salehi K, and Zhian F. Risk of breast cancer in relation to reproductive factors in North-West of Iran, 2013-2014Asian Pac J Cancer Prev 2015; 16:451–455.

Veneroso C, Siegel R, and Levine PH. Early age at first childbirth associated with advanced tumor grade in breast cancerCancer Detect Prev 2008; 32:215–223.

Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studiesPLoS Medicine 2007; 4:1623–27 (e296). Doi: 10.1371/journal.pmed. 0040296.

Williams WV, Carlson K, Mitchell LA, and Raviele K. Association of Combined Estrogen-Progestogen and Progestogen Only Contraceptives with the Development of CancerThe Linacre Quarterly 2018; 85(4): 412–452.

World Health Organization International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Combined Estrogen−Progestogen Contraceptives and Combined Estrogen−Progestogen Menopausal Therapy. 2007; http://monographs.iarc.fr/ENG/Monographs/vol91/mono91.pdf.

World Health Organization International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Combined Estrogen−Progestogen Contraceptives. IARC Monographs 2012; 100A:283–318; http://monographs.iarc.fr/ENG/Monographs/vol100A/mono100A-19.pdf.

Yager JD and Davidson NE. Estrogen Carcinogenesis in Breast CancerEngl J Med 2006; 354:270-282.

[50] Zhu H, Lei X, Feng J, and Wang Y. Oral contraceptive use and risk of breast cancer: a meta-analysis of prospective cohort studiesEur J Contracept Reprod Health Care 2012; 17:402–414.

CERVICAL CANCER

World Health Organization International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Combined Estrogen−Progestogen Contraceptives and Combined Estrogen−Progestogen Menopausal Therapy. 2007; http://monographs.iarc.fr/ENG/Monographs/vol91/mono91.pdf.

World Health Organization International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Combined Estrogen−Progestogen Contraceptives. IARC Monographs 2012; 100A:283–318; http://monographs.iarc.fr/ENG/Monographs/vol100A/mono100A-19.pdf.

International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M, and Sweetland S. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studiesLancet 2007; 370:1609–1621.

Leslie HH, Karasek DA, Harris LF, Chang E, Abdulrahim N, Maloba M, and Huchko MJ. Cervical cancer precursors and hormonal contraceptive use in HIV-positive women: application of a causal model and semiparametric estimation methodsPLoS One 2014; 9:e101090.

Matos A, Moutinho J, Pinto D, and Medeiros R. The influence of smoking and other cofactors on the time to onset to cervical cancer in a southern European populationEur J Cancer Prev 2005; 14:485–491.

McFarlane-Anderson N, Bazuaye PE, Jackson MD, Smikle M, and Fletcher HM. Cervical dysplasia and cancer and the use of hormonal contraceptives in Jamaican womenBMC Womens Health 2008; 8:9.

Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers JM, Herrero R, Franceschi S; International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control studyLancet 2002; 359(9312):1085–1092.

Roura E, Travier N, Waterboer T, de Sanjosé S, Bosch FX, Pawlita M, Pala V, Weiderpass E, Margall N, Dillner J, Gram IT, Tjønneland A, Munk C, Palli D, Khaw KT, Overvad K, Clavel-Chapelon F, Mesrine S, Fournier A, Fortner RT, Ose J, Steffen A, Trichopoulou A, Lagiou P, Orfanos P, Masala G, Tumino R, Sacerdote C, Polidoro S, Mattiello A, Lund E, Peeters PH, Bueno-de-Mesquita HB, Quirós JR, Sánchez MJ, Navarro C, Barricarte A, Larrañaga N, Ekström J, Lindquist D, Idahl A, Travis RC, Merritt MA, Gunter MJ, Rinaldi S, Tommasino M, Franceschi S, Riboli E, and Castellsagué X. The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC CohortPLoS One 2016; 11:e0147029.

Vanakankovit N and Taneepanichskul S. Effect of oral contraceptives on risk of cervical cancerJ Med Assoc Thai 2008; 91:7–12.

Wilson JC, O’Rorke MA, Cooper JA, Murray LJ, Hughes CM, Gormley GJ, and Anderson LA. Non-steroidal anti-inflammatory drug use and cervical cancer risk: a case-control study using the Clinical Practice Research DatalinkCancer Epidemiol 2013; 37:897–904.

Del Rio JP, Allende MI, Molina N, Serrano FG, Molina S, and Vigil P. Steroid Hormones and their Action in Women’s Brains: The Importance of Hormonal BalanceFrontiers in Public Health 2018; May(6) art. 141:1–15.

Gregory Sean T, Hall K, Quast T, Gatto A, Bleck J, Storch EA, and DeBate R. Hormonal contraception, depression and Academic Performance among females attending college in the United StatesPsychiatry Research 2018; 270:111–116.

Keyes Katherine T, Cheslack-Postava K, Westhoff C, Heim CM, Haloossim M, Walsh K, and Koenen K. Association of Hormonal Contraception Use with Reduced levels of Depressive Symptoms: A National Study of Sexually Active women in the United StatesAm J. Epidemiol 2013; 178(9):1378–1388.

Skovlund CW, Mørch LS, Kessling LV, and Lidegaard O. Association of Hormonal Contraception with DepressionJAMA Psychiatry 2016; 73(11):1154–1162.

Skovlund CW, Mørch LS, Kessling LV, Lange T, and Lidegaard, O. Association of Hormonal Contraception with Suicide Attempts and SuicidesAm. J Psychiatry 2018; 175(4):336–342.

Svendal G, Berk M, Pasco JA, and Jacka FN. The use of hormonal contraceptive agents and mood disorders in womenJ Affective Disorders 2012; 140:92–96.

Toffol E, Heiknheimo, Koponene P, Luoto R, and Partonen T. Hormonal contraception and mental health: results of a population based studyHuman Reproduction 2011; 26(11):3085–3093.

Worly Brett L, Gur TL, and Schaffir J. The relationship between progestin hormonal contraception and depression: a systematic reviewContraception 2018; 97:478–489.

Young EA, Kornstein SG, Harvey AT, Wisniewski SR, Barkin J, Fava M, Trivedi MH, and Rush AJ. Influences of Hormone-Based Contraception in Depressive symptoms in Premenopausal Women with Major DepressionPsychoneuroendocrinology 2007; 32(7):843–853.

Baeten JM, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, Ndinya-Achola JO, Jaoko W, and Overbaugh J. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan womenAIDS 2007; 21:1771–1777.

Brind J, Condly SJ, Mosher SW, Morse AR, and Kimball J. Risk of HIV infection in Depot Medroxyprogesterone Acetate (DMPA) users: a systematic review and meta-analysisIssues Law Med 2015; 30:129–139.

Crook AM, Ford D, Gafos M, Hayes R, Kamali A, Kapiga S, Nunn A, Chisembele M, Ramjee G, Rees H, and McCormack S. Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trialHum Reprod 2014; 29:1810–1817.

Govender Y, Avenant C, Verhoog NJ, Ray RM, Grantham NJ, Africander D, and Hapgood JP. The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptorPLoS One 2014; 9:e96497.

Hapgood JP and Tomasicchio M. Modulation of HIV-1 virulence via the host glucocorticoid receptor: towards further understanding the molecular mechanisms of HIV-1 pathogenesisArch Virol 2010; 155:1009-1019. Doi: 10.1007/s00705-010-0678-0.

Hapgood JP, Ray RM, Govender Y, Avenant C, and Tomasicchio M. Differential glucocorticoid receptormediated effects on immunomodulatory gene expression by progestin contraceptives: implications for HIV-1 pathogenesisAm J Reprod Immunol 2014; 71(6):505–512. Doi: 10.1111/aji.12214.

Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J, Coombs RW, Baeten JM; Partners in Prevention HSV/HIV Transmission Study Team. Use of hormonal contraceptives and risk of HIV-1 transmission: A prospective cohort studyLancet Infect Dis 2012; 12:19–26.

Huijbregts RP, Michel KG and Hel Z. Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCsContraception 2014 Aug; 90(2):123–129. Doi: 10.1016/j.contraception.2014.02.006.

Kiddugavu M, Makumbi F, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, Lutalo T, Meehan M, Xianbin, Gray RH; Rakai Project Study Group. Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, UgandaAIDS 2003; 17:233–240.

Kleinschmidt I, Rees H, Delany S, Smith D, Dinat N, Nkala B, and McIntyre JA. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohortContraception 2007; 75:461–467.

Maritz MF, Ray RM, Bick AJ, Tomasicchio M, Woodland JG, Govender Y, Avenant C, and Hapgood JP. Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levelsPLoS One 2018 https://doi.org/10.1371/journal.pone.o196043.

McCoy SI, Zheng W, Montgomery ET, Blanchard K, van der Straten A, de Bruyn G, and Padian NS. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan AfricaAIDS 2013; 27:1001–1009.

Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, Luoto J, Mugerwa R, Padian N, Rugpao S, Brown JM, Cornelisse P, Salata RA; Hormonal Contraception and the Risk of HIV Acquisition (HC-HIV) Study Group. Hormonal contraception and the risk of HIV acquisitionAIDS 2007; 21:85–95.

Morrison CS, Skoler-Karpoff S, Kwok C, Chen PL, van de Wijgert J, Gehret-Plagianos M, Patel S, Ahmed K, Ramjee G, Friedland B, and Lahteenmaki P.. Hormonal contraception and the risk of HIV acquisition among women in South AfricaAIDS 2012; 26:497–504.

Morrison CS, Chen P-L, Kwok C, Baeten JM, Brown J, Crook AM, Van Damme L, Delany-Moretlwe S, Francis SC, Friedland BA, Hayes RJ, Heffron R, Kapiga S, Karim QA, Karpoff S, Kaul R, McClelland RS, McCormack S, McGrath N, Myer L, Rees H, van der Straten A, Watson-Jones D, van de Wijgert JH, Stalter R, and Low N. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysisPLoS Med 2015; 12:e1001778. doi: 10.1371/journal.pmed.1001778.

Myer L, Denny L, Wright TC, and Kuhn L. Prospective study of hormonal contraception and women’s risk of HIV infection in South AfricaInt J Epidemiol 2007; 36:166–174.

Ralph LJ, McCoy SI, Shiu K and Padian NS. Hormonal contraceptive use and women’s risk of HIV acquisition: a meta-analysis of observational studiesLancet Infect Dis 2015; 15:181–189. Doi: 10.1016/S1473-3099(14)71052–1057.

Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, and Thijssen JH. Classification and pharmacology of progestinsMaturitas 2003; 46 (Suppl 1):S7-S16. Doi: 10.1016/j.maturitas.2003.09.014.

Tomasicchio, Michele, Avenant C, Du Toit A, Ray RM, and Hapgood JP. The Progestin-Only Contraceptive Medroxyprogesterone Acetate, but Not Norethisterone Acetate, Enhances HIV-1 Vpr-Mediated Apoptosis in Human CD4+ T Cells through the Glucocorticoid ReceptorPloS One 2013; 8:e62895.

Wand H and Ramjee G. The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infectionsAIDS 2012; 26:375–380.

Lee JJML, Low LL, and Ang SB. Oral Contraception and Female Sexual Dysfunction in Reproductive WomenSexual Medicine Reviews. 2017; 5:31–44.

Gardella B, Porru D, Nappi RE, Daccò MD, Chiesa A, and Spinillo A. Interstitial cystitis is associated with vulvodynia and sexual dysfunction—a case-control studyThe Journal of Sexual Medicine 2011; 8:1726–1734. Doi: 10.1111/j.1743-6109.2011.02251.x. Epub 2011 Apr 7.

Dal’Ava N, Bahamondes L, Bahamondes MV, Bottura BF, and Monteiro I. Body weight and body composition of depot medroxyprogesterone acetate usersContraception 2014; 90(2):182–187.

Dal’Ava N, Bahamondes L, Bahamondes MV, de Oliveira Santos A, and Monteiro I. Body weight and composition in users of levonorgestrel-releasing intrauterine systemContraception 2012; 86(4):350–353.

Dos Santos, PdeNS, Modesto WO, Dal’Ava N, Bahamondes M, Pavin E, and Fernades A. Body composition and weight gain in new users of the three-monthly injectable contraceptive, depot-medroxyprogesterone acetate, after 12 months of follow-upEuropean Journal of Contraception and Reproductive Health Care 2014; 19(6):432–438.

Barad D, Kooperberg C, Wactawski-Wende J, Liu J, Hendrix SL, and Watts NB. Prior oral contraception and postmenopausal fracture: a Womens’ Health Initiative observational cohort studyFertility and Sterility 2005; 84:374–383.

Cooper C, Hannaford P, Croft P, and Kay CR. Oral contraceptive pill use and fractures in women: a prospective studyBone 1993; 14(1):41–45.

Curtis KM and Martins SL. Progestin-only contraception and bone mineral density: a systematic reviewContraception 2006; 73:470–487.

FDA 2004: U.S. Food and Drug Administration. FDA Talk Paper. Black box Warning Added Concerning Longterm Use of Depo-Provera Contraceptive Injection.

http://web.archive.org/web/20070809090332/http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html (accessed 2019 February 23).

Lanza LL, McQuay LJ, Rothman KJ, Bone HG, Kaunitz AM, Harel Z, Ataher Q, Ross D, Arena PL, and Wolter KD. Use of depot medroxyprogesterone acetate contraception and incidence of bone fractureObstetrics and Gynecology 2013; 121(3):593–600.

Lopez LM, Chen M, Mullins Long S, Curtis KM, and Helmerhorst FM. Steroidal contraceptives and bone fractures in women: evidence from observational studies (Review)Cochrane Database of Systematic Reviews 2015; Issue 7. Art. No.: CD009849. DOI: 10.1002/14651858.CD009849.pub3.

Meier C, Brauchli YB, Jick SS, Kraenzlin ME, and Meier CR. Use of depot medroxyprogesterone acetate and fracture riskJournal of Clinical Endocrinology and Metabolism 2010; 95(11):4909–4916.

Memon S, Iversen L, and Hannaford PC. Is the oral contraceptive pill associated with fracture in later life? New Evidence from the Royal College of General Practitioners Oral Contraception StudyContraception 2011; 84(1):40–47.

Michaelsson K, Baron JA, Farahmand BY, and Ljunghall S. Influence of parity and lactation on hip fracture riskAmerican Journal of Epidemiology 2001; 153(12):1166–1172.

Michaelsson K, Baron JA, Farahmand BY, Persson I, and Ljunghall S. Oral-contraceptive use and risk of hip fracture: a case-control studyLancet 1999; 353(9163):1481–1484.

O’Neill TW, Marsden D, Adams JE, and Silman AJ. Risk factors, falls, and fracture of the distal forearm in Manchester, UKJournal of Epidemiology and Community Health 1996; 50(3):288–292.

Parazzini G, Tavani A, Ricci E, and La Vecchia C. Menstrual and reproductive factors and hip fractures in post menopausal womenMaturitas 1996; 24:191–196.

Sirola J, Rikkonen T, Tuppurainen M, Honkanen R, and Kroger H. Should risk of bone fragility restrict weight control for other health reasons in postmenopausal women?—A ten year prospective studyMaturitas 2012; 71(2):162–168.

Tuppurainen M, Honkanen R, Kröger H, Saarikoski S, and Alhava E. Osteoporosis risk factors, gynaecological history and fractures in perimenopausal women—the results of the baseline postal enquiry of the Kuopio Osteoporosis Risk Factor and Prevention StudyMaturitas 1993; 17(2):89–100.

Vessey M, Mant J, and Painter R. Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort studyContraception 1998; 57(4):231–235.

Vestergaard P, Rejnmark L, and Mosekilde L. Fracture risk in very young women using combined oral contraceptivesContraception 2008a; 78(5):358–364.

Vestergaard P, Rejnmark L, and Mosekilde L. Oral contraceptive use and risk of fracturesContraception 2006; 73(6):571–576.

Vestergaard P, Rejnmark L, and Mosekilde L. The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish womenContraception 2008b; 78(6):459–464.

Wei S, Venn A, Ding C, Foley S, Laslett L, and Jones G. The association between oral contraceptive use, bone mineral density and fractures in women aged 50-80 yearsContraception 2011; 84(4):357–362.

Women’s Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational studyControlled Clinical Trials 1998; 19(1):61–109.

Gallo MF, Lopez LM, Grimes DA, Carayon F, Schulz KF, and Helmerhorst FM. Combination contraceptives: effects on weightCochrane Database of Systematic Reviews 2014; Issue 1. Art. No.: CD003987.

Lopez LM, Ramesh S, Chen M, Edelman A, Otterness C, Trussell J, and Helmerhorst FM. Progestin-only contraceptives: effects on weight (Review)Cochrane Database of Systematic Reviews 2016; Issue 8. Art. No.: CD008815.

Lopez LM, Ramesh S, Chen M, Edelman A, Otterness C, Trussell J, and Helmerhorst FM. Progestin-only contraceptives: effects on weightCochrane Database Syst Reviews 2016a Aug 28;(8):CD008815. Doi: 10.1002/14651858.

Modesto W, dos Santos PdeNS, Correia VM, Borges L, and Bahamondes L. Weight variation in users of depotmedroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of useEuropean Journal of Contraception and Reproductive Health Care 2015; 20(1):57–63.

Napolitano A, Zanin R, Palma F, Romani C, Grandi G, Di Carlo C, and Cagnacci A. Body composition and resting metabolic rate of perimenopausal women using continuous progestogen contraceptionEuropean Journal of Contraception and Reproductive Health Care 2015 Aug 25 [Epub ahead of print]:1–8.

Pantoja M, Medeiros T, Baccarin MC, Morais SS, Bahamondes L, and Fernandes AM. Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptiveContraception 2010; 81(2):107–111.

Taneepanichskul S, Reinprayoon D, Khaosaad P. Comparative study of weight change between long-term DMPA and IUD acceptorsContraception 1998; 58(3):149–151.

Vickery Z, Madden T, Zhao Q, Secura GM, Allsworth JE, and Peipert JF. Weight change at 12 months in users of three progestin-only contraceptive methodsContraception 2013; 88(4):503–508.

Articles on Birth Control Side Effects

can you ovulate on birth control, breakthrough ovulation, breakthrough ovulation on birth control, signs of ovulation on birth control, breakthrough ovulation symptoms

Birth Control Side Effects

Can you ovulate on birth control?

marital problems birth control, divorce birth control, birth control cause divorce, birth control cause relationship problems

Relationship health: NFP vs Birth Control

Marital problems as a side effect of birth control use 

coming off the pill edens story, coming off the pill eden, coming off the pill

Birth Control Side Effects

Coming Off the Pill: Eden’s Story

what men know about birth control

“She’s not herself.” When someone you love is struggling with birth control side effects

What men know about birth control, based on my conversations with “the boys”

is it safe to stop your period, is it safe to stop your period indefinitely, menstrual suppression, continuous menstrual suppression, is it bad to stop your period, is it bad to stop your period with birth control, is it bad to stop your period with the pill

Understanding your menstrual cycle

Is it safe to stop your period indefinitely? 

plan b, plan b abortifacient, can plan b cause abortion,

Birth Control Side Effects

Can Plan B cause an abortion? 

Birth Control Side Effects

Coming off the Pill: Taryn’s Story

Birth Control Side Effects

Coming off the Pill: Hanna’s Story

quit the pill, quitting the pill, getting off the bill, coming off birth control, getting off birth control, stopping birth control, stop taking birth control, stop taking the pill. stopping the birth control pill, coming off the pill

Birth Control Side Effects

Coming off the Pill: Cassie’s Story

missed period pills mpp contraception abortifacient plan b plan c emergency contraception early abortion avoid pregnancy test fertility awareness natural family planning menstrual cycle charting natural womanhood natural birth control nfp fam fabm fertility awareness based method, mifepristone, misoprostol, emergency contraception, abortion pill

Birth Control Side Effects

What are Missed Period Pills?

Natural Womanhood, Fertility Awareness Based Methods, Natural Family Planning, NFP, FABM, FAM, birth control side effects, womens health, reproductive health, fertility awareness, taking charge of your fertility, know more about your body, understanding fertility, understanding fertility health, improving fertility health, improving women's health, natural birth control, libido, sex drive, sexual desire, desire, sexy, love, love-making, lovemaking, connection, birth control and low libido

Birth Control Side Effects

Libido in the Time of COVID-19

Natural Womanhood, Fertility Awareness Based Methods, Natural Family Planning, NFP, FABM, FAM, birth control side effects, womens health, reproductive health, fertility awareness, taking charge of your fertility, know more about your body, understanding fertility, understanding fertility health, improving fertility health, improving women's health, natural birth control, IUD and depression, copper IUD and depression, copper toxicity, IUD removal, heavy bleeding, racing thoughts, palpitations

Birth Control Side Effects

Removing My IUD Removed My Depression

Natural Womanhood Fertility Awareness Methods FABM Natural Family PLanning NFP charting menstrual cycle apps birth control side effects health risks iud the pill hormonal contraceptives

Birth Control Side Effects

2019: A Year in Review

Natural Womanhood, Fertility Awareness Based Methods, Natural Family Planning, NFP, FABM, FAM, birth control side effects, womens health, reproductive health, fertility awareness, copper Iud side efects, copper IUD toxicity, copper toxicity, birth control side effects, IUD side effects, copper IUD side effects, birth control side effects, birth control answers, natural birth control, birth control education, learn about birth control side effects,

Fertility Awareness Around the World

Surviving a Toxic Reaction to the Copper IUD

Natural Womanhood, Fertility Awareness Based Methods, Natural Family Planning, NFP, FABM, fertility awareness, birth control side effects, the Pill side effects, birth control cause blood blots, the pill causes blood clots, hormonal birth control risk of blood clots, birth control risks, blood clots on birth control

Birth Control Side Effects

Blood Clots and Hormonal Birth Control

Nigeria Natural Love Stories Film screening

Birth Control Side Effects

An update on our FAM campaign in Nigeria

Birth Control Side Effects

Getting pregnant on birth control

menstrual cycle charting period tracking fertility awareness methods fam nfp natural family planning on the pill birth control oral contraceptives iud implant can you chart on birth control natural womanhood

Birth Control Side Effects

Can I chart when I’m on the pill?

Birth Control Side Effects

Is there a Contraception Conspiracy?

Eggs

Birth Control Side Effects

Problem-solving, problem-creating America

Natural Womanhood

Birth Control Side Effects

Save the earth…one woman at a time

Birth Control Side Effects

Athlete drops the Pill and stops anemia

Birth Control Side Effects

You’re not yourself on the Pill

Birth Control Side Effects

Listen to “women’s talk”

Birth Control Side Effects

Who cares about breast cancer?

View related articles
Copyright © 2024 Natural Womanhood